Page 81 - Read Online

Page 16 of 19 Serzan et al. J Cancer Metastasis Treat 2021;7:39 https://dx.doi.org/10.20517/2394-4722.2021.76

guide first line and sequential treatment strategies.

DECLARATIONS
Authors’ contributions
Responsible for the paper: Atkins MB
Concept, design, definition of intellectual content: Atkins MB
Literature search: Serzan M, Atkins MB
Manuscript preparation: Serzan M, Atkins MB
Manuscript editing: Serzan M, Atkins MB
Manuscript revision: Serzan M, Atkins MB

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer 2019;144:1941-53. DOI PubMed
2. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol 2020;11:79-87. DOI PubMed
PMC
3. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with
conventional clear cell renal cell carcinoma. J Urol 2005;173:48-51. DOI PubMed
4. Surveillance, Epidemiology, and End Results Program, National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer.
Available from: https://seer.cancer.gov/statfacts/html/kidrp.html [Last accessed on 21 May 2021].
5. Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol 2020;16:435-51. DOI PubMed
6. Ricketts CJ, De Cubas AA, Fan H, et al; Cancer Genome Atlas Research Network. The cancer genome atlas comprehensive molecular
characterization of renal cell carcinoma. Cell Rep 2018;23:3698. DOI PubMed
7. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin
Cancer Res 2008;14:4726-34. DOI PubMed PMC
8. Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013;23:18-25. DOI PubMed PMC
9. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 2015;15:55-64. DOI PubMed
10. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients
with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90. DOI PubMed PMC
11. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized
phase III trial. J Clin Oncol 2010;28:1061-8. DOI PubMed
12. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31.
DOI PubMed
13. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal
cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 2017;35:591-7. DOI PubMed PMC
14. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.